Shares in Anglo-Swedish drug have closed down 8% in UK trade after the failure of its Iressa drug in a major clinical trial."This would be two of the three blockbuster drugs that were meant to power the company forward failing... and we've got risks on Crestor," said Nick Turner, analyst at brokers Jefferies.The lung cancer drug did not significantly prolong survival in patients with the disease.AstraZeneca has now appointed a new executive director to the board.Shares